Efficacy of chimeric antigen receptor T-cell therapy in testicular relapse of pediatric acute lymphoblastic leukemia: a multicenter retrospective study - PubMed
5 hours ago
- #pediatric leukemia
- #CAR-T therapy
- #testicular relapse
- Testicular relapse is a common extramedullary recurrence in pediatric acute lymphoblastic leukemia (ALL).
- The study analyzed 66 patients from 13 medical centers, focusing on treatment outcomes post-relapse.
- Median time from initial diagnosis to testicular relapse was 37 months.
- 2-year overall survival (OS) rate post-relapse was 86.1% after a median follow-up of 33 months.
- CAR-T therapy showed a 2-year OS of 90.7%, comparable to conventional treatments (81.7%).
- In isolated testicular relapse cases, CAR-T therapy and orchiectomy had 2-year OS rates of 92.3% and 100%, respectively.
- CAR-T therapy is safe and effective, with potential advantages in preserving life quality for long-term survivors.